62858 Federal Register / Vol. 72, No.

215 / Wednesday, November 7, 2007 / Notices

Dated: October 29, 2007. ACTION: Notice. SUPPLEMENTARY INFORMATION: The

Elaine L. Baker, holders of the applications listed in the
Director, Management Analysis and Services SUMMARY: The Food and Drug table in this document have informed
Office, Centers for Disease Control and Administration (FDA) is withdrawing FDA that these drug products are no
Prevention. approval of 73 new drug applications longer marketed and have requested that
[FR Doc. E7–21842 Filed 11–6–07; 8:45 am] (NDAs) and 62 abbreviated new drug FDA withdraw approval of the
BILLING CODE 4163–18–P applications (ANDAs) from multiple applications. The applicants have also,
applicants. The holders of the by their requests, waived their
applications notified the agency in opportunity for a hearing.
DEPARTMENT OF HEALTH AND
writing that the drug products were no
HUMAN SERVICES
longer marketed and requested that the
Food and Drug Administration approval of the applications be
withdrawn.
[Docket No. 2007N–0427]
EFFECTIVE DATE: December 7, 2007.
Lederle Laboratories et al.; Withdrawal FOR FURTHER INFORMATION CONTACT:
of Approval of 73 New Drug Florine P. Purdie, Center for Drug
Applications and 62 Abbreviated New
Evaluation and Research (HFD–7), Food
Drug Applications
and Drug Administration, 5600 Fishers
AGENCY: Food and Drug Administration, Lane, Rockville, MD 20857, 301–594–
HHS. 2041.

Application No. Drug Applicant

NDA 6–459 Hetrazan (diethylcarbamaxine citrate) Tablets and Syrup Lederle Laboratories, c/o Wyeth Pharmaceuticals, Inc.,
P.O. Box 8299, Philadelphia, PA 19101–8299

NDA 6–799 Rubramin and Rubramin PC (cyanocobalamin injection Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ
USP) 08543–4000

NDA 7–517 Tapazole (methimazole tablets USP), 5 milligrams (mg) King Pharmaceuticals, Inc., 501 Fifth St., Bristol, TN
and 10 mg 37620

NDA 7–942 Sus-Phrine (epinephrine) Injection Forest Laboratories, Inc., Harborside Financial Center,
Plaza Three, suite 602, Jersey City, NJ 07311

NDA 9–319 Ambenyl Expectorant and Ambenyl Cough Syrup Do.

NDA l0–533 PBZ SR (tripelennamine HCl USP) Extended-Release Novartis Pharmaceuticals Corp., One Health Plaza, East
Tablets Hanover, NJ 07936–1080

NDA 10–744 Darbid (isopropamide iodide) Tablets SmithKline Beecham Corp., d/b/a/ GlaxoSmith Kline, P.O.
Box 13398, Five Moore Dr., Research Triangle Park,
NC 27709

NDA 10–909 Miradon (anisindione) Tablets Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ
07033

NDA 11–213 Trilafon (perphenazine) Injection, 5 mg/milliliter (mL) Do.

NDA 11–283 Kenacort (tramcinolone) Tablets Bristol-Myers Squibb Co.

NDA 11–808 Mellaril (thioridazine HCl) Tablets Novartis Pharmaceuticals Corp.

NDA 12–145 Prolixin (fluphenazine HCl) Elixir, 0.5 mg/mL Apothecon, c/o Bristol-Myers Squibb Co., P.O. Box 4500,
Princeton, NJ 08543–4500

NDA 12–313 BIO-CLEAR (dibenzothiophene) Cream Helena Rubinstein, 202 Rodney Bldg., 3411 Silverside
Rd., Wilmington, DE 19810

NDA 12–665 Velban (vinblastine sulfate) for Injection Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN
46285

NDA 12–678 Tolbutamide Tablets Sandoz Inc., 227–15 North Conduit Ave., Laurelton, NY
11413

NDA 12–796 Quinidex Extentabs (quinidine sulfate extended-release Wyeth Pharmaceuticals, Inc.
pwalker on PROD1PC71 with NOTICES

tablets USP)

NDA 14–103 Oncovin (vincristine sulfate) Injection Eli Lilly and Co.

NDA 14–242 Dexacort (dexamethasone sodium phosphate) Turbinaire UCB, 755 Jefferson Rd., Rochester, NY 14623

VerDate Aug<31>2005 16:14 Nov 06, 2007 Jkt 214001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1
 Federal Register / Vol. 72, No. 215 / Wednesday, November 7, 2007 / Notices 62859

Application No. Drug Applicant

NDA 14–262 Solbar (dioxybenzone and oxybenzone) Cream Person & Covey, Inc., 616 Allen Ave., Glendale, CA
91201

NDA 16–363 Lasix (furosemide) 10–mg/mL Injection Sanofi-Aventis, 300 Somerset Corporate Blvd., Bridge-
water, NJ 08807–0977

NDA 16–408 WILDROOT (pyrithione zinc) Hair Groom and Grenadier Colgate-Palmolive Co., 909 River Rd., Piscataway, NJ
Hair Groom 08854–5596

NDA 16–729 Ferrous Citrate Fe 59 Injection Mallinckrodt Inc., 675 McDowell Blvd., P.O. Box 5840, St.
Louis, MO 63134

NDA 16–820 Emete-Con (benzquinamide HCl) Injection Pfizer, Inc., 235 East 42nd St., New York, NY 10017

NDA 16–847 Isopaque 440 (metrizoate sodium, meglumine metrizoate, GE Healthcare, 101 Carnegie Center, Princeton, NJ
calcium metrizoate, and metrizoate magnesium) Injec- 08540
tion

NDA 17–430 Neggram (nalidixic acid USP) Suspension Sanofi-Aventis

NDA 17–466 Bricanyl (terbutaline sulfate) Injection Sanofi-Aventis

NDA 17–506 Isopaque 280 (metrizoic acid, meglumine, and calcium) GE Healthcare
Injection

NDA 17–613 Lotrimin (clotrimazole) Topical Solution, 1% Schering Corp.

NDA 17–618 Bricanyl (terbutaline sulfate) Tablets Sanofi-Aventis

NDA 17–619 Lotrimin (clotrimazole) Cream, 1% Schering Corp.

NDA 17–668 Tenuate (diethylpropion HCl) Tablets, 25 mg Sanofi-Aventis

NDA 17–669 Tenuate (diethylpropion HCl) Extended-Release Tablets, Sanofi-Aventis

75 mg

NDA 17–688 Lasix (furosemide) Oral Solution, 10 mg/mL Sanofi-Aventis

NDA 17–719 Dimeray (iocarmate meglumine) Injection Mallinckrodt Inc.

NDA 17–725 Sodium Pertechnetate Tc–99m (technectium Tc–99m so- Mallinckrodt Inc.
dium pertechnetate)

NDA 17–730 Isopaque 370 (metrizoic acid and meglume) Injection GE Healthcare

NDA 17–769 Calcimar (calcitonin salmon) Injection Sanofi-Aventis

NDA 17–838 Lungaggregate Reagent GE Healthcare

NDA 17–848 Tc–99m Lungaggregate Do.

NDA 17–907 Glucoscan Kit for the Preparation of Technetium Tc–99m Bristol-Myers Squibb Pharma Co., Chestnut Run Plaza,
Gluceptate 974 Centre Rd., Wilmington, DE 19805

NDA 17–923 Mellaril-S (thioridazine HCl) Oral Suspension Novartis Pharmaceuticals Corp.

NDA 17–956 Tepanil (diethylpropion HCl) Ten-Tabs 3M Pharmaceuticals, 3M Center, Bldg 0275–05–W–12,
St. Paul, MN 55144–1000

NDA 18–000 Bricanyl (terbutaline sulfate) Inhaler Sanofi-Aventis

NDA 18–067 Cinobac (cinoxacin) Capsules, 250 mg and 500 mg Eli Lilly and Co.

NDA 18–088 Krypton Kr–81m Gas Generator GE Healthcare

NDA 18–148 Nasalide (flunisolide) Nasal Spray IVAX Research, Inc., 4400 Biscayne Blvd., Miami, FL
33137

NDA 18–489 Technescan HIDA (kit for the preparation of technetium Draximage, 16751 Autoroute TransCanada Highway,
Tc–99m lidofenin injection) Kirkland, Quebec, H9H 4J4, Canada
pwalker on PROD1PC71 with NOTICES

NDA 18–519 Irrigation Solution G (citric acid and sodium carbonate) Baxter Healthcare Corp., 1620 Waukegan Rd., MPGR-AL,
McGaw Park, IL 60085

NDA 18–554 Eulexin (flutamide) Capsules Schering Corp.

VerDate Aug<31>2005 16:14 Nov 06, 2007 Jkt 214001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1
 62860 Federal Register / Vol. 72, No. 215 / Wednesday, November 7, 2007 / Notices

Application No. Drug Applicant

NDA 18–700 Inocor (inamrinone lactate) Injection, 5 mg base/mL Sanofi-Synthelabo Inc., c/o Sanofi-Aventis, 300 Somerset
Corporate Blvd., P.O. Box 6977, Bridgewater, NJ
08807–0977

NDA 18–770 Tornalate (bitolterol mesylate) Metered-Dose Inhaler Sanofi-Aventis

NDA 18–813 Lotrimin (clotrimazole) Lotion, 1% Schering Corp.

ANDA 18–862 Betatrex (betamethasone valerate cream USP, 0.1%) Savage Laboratories, 60 Baylis Rd., Melville, NY 11747

ANDA 18–863 Betatrex (betamethasone valerate ointment USP, 0.1%) Do.

ANDA 18–867 Betatrex (betamethasone valerate lotion USP, 0.1%) Do.

NDA 19–084 Nizoral (ketoconazole) Cream, 2% Johnson & Johnson Pharmaceutical Research & Develop-
ment, LLC, c/o Janssen Pharmaceutical Products, LP,
1125 Trenton-Harbourton Rd., P.O. Box 200, Titusville,
NJ 08560

NDA 19–284 Oral Colonic Lavage (OCL) (sodium chloride, sodium bi- Hospira, Inc., 275 North Field Dr., Bldg. 2–J45–2, Lake
carbonate, sodium sulfate, potassium chloride, and Forest, Il 60045–5046
polyethelene glycol 3350)

NDA 19–408 Diprolene (betamethasone dipropionate) Schering Corp.

NDA 19–459 Photoplex (7% padimate O and 3% avobenzone) Lotion Allergan, 2525 Dupont Dr., P.O. Box 19534, Irvine, CA
92623–9534

NDA 19–520 Travasol (amino acid) in Dextrose Injection Baxter Healthcare Corp.

NDA 19–545 Didronel (etidronate disodium) Injection MGI Pharma, Inc., 5775 West Old Shakopee Rd., suite
100, Bloomington, MN 55437–3174

NDA 19–548 Tornalate (bitolterol mesylate) Inhalatioon Solution, 0.2% Sanofi-Aventis

NDA 19–576 Nizoral (ketoconazole) Cream, 2% Johnson & Johnson Pharmaceutical & Development, LLC

NDA 19–648 Nizoral (ketoconazole) Cream, 2% Do.

NDA 20–091 Imagent (perflubron) Alliance Pharmaceuticals Corp., 4660 La Jolla Dr., suite
740, San Diego, CA 92122

NDA 20–147 Travasol (amino acid) with Electrolytes in Dextrose Injec- Baxter Healthcare Corp.
tion

NDA 20–228 Atrovent (ipratropium bromide) Inhalation Solution Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridge-
bury Rd., P.O. Box 368, Ridgefield, CT 06877–0368

NDA 20–303 Prempro/Premphase (conjugated estrogens and Wyeth Pharmaceuticals, Inc.

medroxyprogesterone acetate) Tablets

NDA 20–315 Orlaam (levomethadyl acetate HCl) Oral Solution Roxane Laboratories, P.O. Box 16532, Columbus, OH
43216–6532

NDA 20–486 Vanceril (beclomethasone dipropionate) Double Strength Schering Corp.

Aerosol

NDA 20–887 AcuTect Kit for the Preparation of Technetium Tc–99m CIS-US, Inc., 10 De Angelo Dr., Bedford, MA 01730
Apticide Injection

NDA 21–012 Neo-Tect Kit for the Preparation of Technetium Tc–99m Do.
Depreotide Injection

NDA 21–075 Nutropin Depot (somatropin recombinant) Genentech Inc., 1 DNA Way MSι242, South San Fran-
cisco, CA 94080–4990

ANDA 40–098 Acetaminophen and Codeine Phosphate Oral Solution Clonmel Healthcare, Ltd., c/o STADA Pharmaceuticals
USP Inc., U.S. Agent, 5 Cedar Brook Dr., Cranbury, NJ
pwalker on PROD1PC71 with NOTICES

08512

NDA 50–477 Nebcin (tobramycin sulfate) for Injection Eli Lilly and Co.

NDA 50–519 Nebcin (tobramycin sulfate) for Injection Do.

VerDate Aug<31>2005 16:14 Nov 06, 2007 Jkt 214001 PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1
 Federal Register / Vol. 72, No. 215 / Wednesday, November 7, 2007 / Notices 62861

Application No. Drug Applicant

NDA 50–678 Dynabac (dirithromycin delayed-release tablets USP) Lilly Research Laboratories, Lilly Corporate Center, Indi-
anapolis, IN 46285

ANDA 60–212 Grisactin (griseofulvin microcrystalline) Tablets, 500 mg Wyeth Ayerst Laboratories, c/o Wyeth Pharmaceuticals,
P.O. Box 8299, Philadelphia, PA 19101

ANDA 60–570 Fungizone (amphotericin B lotion USP), 3% Apothecon, c/o Bristol-Myers Squibb Co.

ANDA 60–751 NEO-CORTEF (neomycin sulfate and hydrocortisone ace- Pharmacia & Upjohn Co., c/o Pfizer, Inc., 235 East 42nd
tate) Ointment St., New York, NY 10017

ANDA 61–007 Terramycin (oxytetracycline HCl, polymyxin B sulfate) Pfizer, Inc.

Topical Ointment with Polymyxin B Sulfate

ANDA 61–131 Nystatin Powder USP Clonmel Healthcare, Ltd., c/o STADA Pharmaceuticals
Inc.

ANDA 61–411 Veetids (penicillin V potassium tablets USP), 250 mg and Apothecon, c/o Bristol-Myers Squibb Co.
500 mg

ANDA 61–737 ZIBA-Rx (bacitracin zinc USP) X-GEN Pharmaceuticals, Inc., P.O. Box 1148, Elmira, NY
14902

ANDA 61–859 Anspor (cephradine) Capsules, 250 mg and 500 mg GlaxoSmithKline, One Franklin Plaza, P.O. Box 7929,
Philadelphia, PA 19101–7929

ANDA 61–866 Anspor (cephradine) for Oral Suspension Do.

ANDA 61–876 Cerubidine Injection (daunorubice HCl for injection USP) Sanofi-Aventis

ANDA 62–519 Nystex (nystatin) Oral Suspension USP, 100,000 units/mL Savage Laboratories

ANDA 62–560 Mandol (cefamadole nafate for injection USP) Eli Lilly and Co.

ANDA 62–739 Tazidime (ceftazidime) Do.

ANDA 62–745 Cephalexin Tablets USP Do.

ANDA 62–888 Principen (ampicillin capsules USP), 250 mg and 500 mg Apothecon, c/o Bristol-Myers Squibb Co.

ANDA 62–926 Rubex (doxorubicin HCl for injection USP) Bristol-Myers Squibb Co.

ANDA 63–021 Kanamycin Sulfate Injection USP, 75 mg/2 mL Loch Pharmaceuticals, c/o Bedford Laboratories, A Divi-
sion of Ben Venue Laboratories, Inc., 300 Northfield
Rd., Bedford, OH 44146

ANDA 63–022 Kanamycin Sulfate Injection USP, 500 mg/2 mL Do.

ANDA 63–025 Kanamycin Sulfate Injection USP, 1 gram (g)/3 mL Do.

ANDA 63–099 Trimox (amoxicillin capsules USP), 250 mg and 500 mg Apothecon, c/o Bristol-Myers Squibb Co.

ANDA 70–867 Vincrex (vincristine sulfate for injection USP), 5 mg/vial Bristol-Myers Squibb Co.

ANDA 71–742 Clorazepate Dipotassium Capsules, 3.75 mg Clonmel Healthcare, Ltd., c/o STADA Pharmaceuticals
Inc.

ANDA 71–743 Clorazepate Dipotassium Capsules, 7.5 mg Do.

ANDA 71–744 Clorazepate Dipotassium Capsules, 15 mg Do.

ANDA 72–326 Fenoprofen Calcium Tablets USP, 600 mg Do.

ANDA 72–507 Methyldopa and Hydrochlorothiazide Tablets USP, 250 Do.

mg/15 mg

ANDA 72–508 Methyldopa and Hydrochlorothiazide Tablets USP, 250 Do.

mg/25 mg
pwalker on PROD1PC71 with NOTICES

ANDA 72–509 Methyldopa and Hydrochlorothiazide Tables USP, 500 Do.

mg/30 mg

ANDA 72–510 Methyldopa and Hydrochlorothiazide Tablets USP, 500 Do.

mg/50 mg

VerDate Aug<31>2005 16:14 Nov 06, 2007 Jkt 214001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1
 62862 Federal Register / Vol. 72, No. 215 / Wednesday, November 7, 2007 / Notices

Application No. Drug Applicant

ANDA 72–705 Prazosin HCl Capsules USP, 1 mg Do.

ANDA 72–706 Prazosin HCl Capsules USP, 2 mg Do.

ANDA 72–707 Prazosin HCL Capsules USP, 5 mg Do.

ANDA 74–258 Metoprolol Tartrate Tablets USP, 50 mg and 100 mg Apothecon, c/o Bristol-Myers Squibb Co.

ANDA 74–423 Captopril Tablets USP, 12.5 mg, 25 mg, 50 mg, and 100 Clonmel Healthcare, Ltd., c/o of STADA Pharmaceuticals
mg Inc.

ANDA 74–472 Captopril Tablets USP, 12.5 mg, 25 mg, 50 mg, and 100 Apothecon, c/o Bristol-Myers Squibb Co.
mg

ANDA 75–407 Morphine Sulfate Extended-Release Tablets USP, 15 mg Clonmel Healthcare, Ltd., c/o STADA Pharmaceuticals
Inc.

ANDA 80–745 Aristocort (triamcinolone acetonide) Ointment, 0.5% Astellas Pharma US, Inc., Three Parkway North, Deer-
field, IL 60015–2537

ANDA 80–750 Aristocort (triamcinolone acetonide) Ointment, 0.1% Do.

ANDA 83–015 Aristocort (triamcinolone acetonide) Cream, 0.5% Do.

ANDA 83–016 Aristocort (triamcinolone acetonide) Cream, 0.1% Do.

ANDA 83–017 Aristocort (triamcinolone acetonide) Cream, 0.025% Do.

ANDA 83–149 PBZ (tripelennamine HCl) Tablet, 25 mg Novartis Pharmaceuticals Corp., 59 Route 10, East Han-
over, NJ 07936–1080

ANDA 83–317 Propoxyphene HCl Capsules, 65 mg Impax Laboratories, Inc., 30831 Huntwood Ave., Hay-
ward, CA 94544

ANDA 83–380 Aristogel (triamcinolone acetonide) Gel, 0.1% Astellas Pharma US, Inc.

ANDA 83–881 Aristocort A (triamcinolone acetonide) Spray Do.

ANDA 86–212 Chlordiazepoxide HCl Capsules, 25 mg Impax Laboratories, Inc.

ANDA 86–213 Chlordiazepoxide Capsules, 5 mg Do.

ANDA 86–358 Mexate (methotrexate sodium for injection) Bristol-Myers Squibb Co.

ANDA 86–926 Tolbutamide Tablets USP, 500 mg Clonmel Healthcare, Ltd., c/o STADA Pharmaceuticals
Inc.

ANDA 87–011 Quinidine Sulfate Tablets USP, 200 mg Do.

ANDA 87–677 Hydrocodone Bitartrate and Acetaminophen B.F. Ascher & Co., Inc., 15501 West 109th St., Lenexa,
KS 66219

ANDA 87–887 TRYSUL (triple sulfa vaginal cream USP) Savage Laboratories

ANDA 88–584 DHC Plus (dihydrocodeine bitartrate, acetaminophen, and The Purdue Frederick Co., One Stamford Forum, Stam-
caffeine) Capsules ford, CT 06901–3431

ANDA 88–760 Mexate-AQ (methotrexate sodium injection USP), 25 mg Bristol-Myers Squibb Co.

ANDA 88–780 Aristocort A Ointment (triamcinolone acetonide ointment Astellas Pharma US, Inc.
USP), 0.1%

ANDA 88–781 Aristocort A (triamcinolone acetonide) Ointment, 0.5% Do.

ANDA 88–944 Sedapap (butalbital and acetaminophen) Tablets, 50 mg/ Merz Pharmaceuticals, LLC, 4215 Tudor Lane, Greens-
650 mg boro, NC 27410

ANDA 89–887 Mexate-AQ Preserved (methotrexate sodium injection Bristol-Myers Squibb Co.
USP), 25 mg/mL
pwalker on PROD1PC71 with NOTICES

Therefore, under section 505(e) of the delegated to the Director, Center for applications listed in the table in this
Federal Food, Drug, and Cosmetic Act Drug Evaluation and Research, by the document, and all amendments and
(21 U.S.C. 355(e)) and under authority Commissioner, approval of the

VerDate Aug<31>2005 16:14 Nov 06, 2007 Jkt 214001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1
 Federal Register / Vol. 72, No. 215 / Wednesday, November 7, 2007 / Notices
supplements thereto, is hereby
withdrawn, effective December 7, 2007.
Dated: October 26, 2007.
Douglas C. Throckmorton,
Deputy Director, Center for Drug Evaluation
and Research.
[FR Doc. E7–21886 Filed 11–6–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
[CIS No. 2427–07; DHS Docket No. USCIS–
2007–0054]
RIN No. 1615–ZA62
Announcement of a Stakeholder
Meeting on the Evaluation of E-Verify
AGENCY: U.S. Citizenship and
Immigration Services, DHS.
ACTION: Notice of meeting.
SUMMARY: The E-Verify program,
formerly Basic Pilot, is an online tool
that allows participating employers to
confirm the employment eligibility of
their newly hired employees, regardless
of citizenship, to help maintain a stable,
legal workforce. The purpose of this
Notice is to announce to interested
members of the public a stakeholder
meeting on the evaluation of the E-
Verify Program to identify program
strengths and weaknesses from multiple
perspectives and to assist the evaluation
staff in prioritizing research topics.
Date and Time: The meeting will be
held on Tuesday, November 27, 2007,
from 8:30 a.m. to 5 p.m.
ADDRESSES: The meeting will be held at
the Washington Court Hotel, 525 New
Jersey Avenue, NW., Washington, DC
20001.
FOR FURTHER INFORMATION CONTACT:
Speckhard, U.S. Citizenship and
Immigration Services (USCIS),
Department of Homeland Security,
Office of Policy & Strategy, 20
Massachusetts Avenue, NW., Room
4012, Washington, DC 20529.
Telephone: (202) 272–1470. Research
contact: Ms. Marsha Lyons, Westat,
1650 Research Boulevard, Rockville,
MD 20850. Telephone: (301) 517–4050,
Fax: (301) 294–3992. E-mail:
MarshaLyons@westat.com.
SUPPLEMENTARY INFORMATION: On
September 15, 1997, the legacy
pwalker on PROD1PC71 with NOTICES
Immigration and Naturalization Service
(INS) published a notice in the Federal
Register describing pilot programs that
were required by section 403 of the
Illegal Immigration Reform and
VerDate Aug<31>2005 16:14 Nov 06, 2007 Jkt 214001
Immigrant Responsibility Act of 1996
(IIRIRA). On December 20, 2004, the
U.S. Citizenship and Immigration
Services (USCIS) announced the
extension of one of these programs, the
Basic Pilot, to November 30, 2008.
Renamed E-Verify, the current program
constitutes an online modification of the
Basic Pilot and allows participating
employers to confirm the employment
eligibility of their newly hired
employees regardless of citizenship to
help maintain a stable, legal workforce.
E-Verify is operated jointly by USCIS
and the Social Security Administration.
An evaluation of the current E-Verify
program is being conducted by Westat,
Inc. This notice announces a public
meeting to seek stakeholder input
regarding the E-Verify program.
Summary of Agenda
• Introductions and Purpose.
• Update on E-Verify.
• Overview of the Key Findings of the
FY2007 evaluation and the current
evaluation goals.
• Break-out group discussions to
address topics such as using biometrics
for verification, resolving tentative
confirmations, timing of employee
verifications, and focusing on specific
types of employers (i.e., designated
agents, employers using designated
agents, employment agencies and
temporary help agencies, inactive
employers).
• Reports from break-out groups.
• Questions and comments.
Public Participation
The meeting is open to the public, but
advance notice of attendance is
requested to ensure adequate seating. In
the event that requests for attendance
exceed available space, it may not be
possible to honor all requests. Persons
planning to attend should notify Ms.
Lyons at least 5 days prior to the
Sara meeting.
Dated: November 1, 2007.
Jonathan R. Scharfen,
Deputy Director, U.S. Citizenship and
Immigration Services.
[FR Doc. E7–21829 Filed 11–6–07; 8:45 am]
BILLING CODE 4410–10–P
DEPARTMENT OF THE INTERIOR
Bureau of Land Management
[WO–260–09–1060–00–24 1A]
Notice of Extension for the Call for
Nominations for the Wild Horse and
Burro Advisory Board
AGENCY: Bureau of Land Management,
Interior.
PO 00000 Frm 00052 Fmt 4703 Sfmt 4703
62863
ACTION: Notice of Extension.
SUMMARY: The purpose of this notice is
to extend the submission date to solicit
nominations for the Wild Horse and
Burro Advisory Board. The Federal
Register notice for nominations
published in the Federal Register on
September 17, 2007 [72 FR 52906].
DATES: This notice extends the date to
December 7, 2007.
ADDRESSES: The nominations should be
submitted to the National Wild Horse
and Burro Program, Bureau of Land
Management, Department of Interior,
P.O. Box 12000, Reno, Nevada 89520–
0006, Attn: Ramona DeLorme: fax (775)
861-6711.
FOR FURTHER INFORMATION CONTACT: Don
Glenn, Acting Division Chief, Wild
Horse and Burro Group, (202) 452–5082.
Individuals who use a
telecommunications device for the deaf
(TDD) may reach Ms. DeLorme at any
time by calling the Federal Information
Relay Service at 1 (800) 877–8339.
Dated: October 30, 2007.
Bud Cribley,
Deputy Assistant Director, Renewable
Resources and Planning.
[FR Doc. E7–21887 Filed 11–6–07; 8:45 am]
BILLING CODE 4310–84–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–613]
In the Matter of Certain 3G Mobile
Handsets and Components Thereof;
Notice of Commission Decision Not To
Review an Initial Determination
Granting Complainants’ Motion To
Amend the Complaint and Notice of
Investigation
AGENCY: U.S. International Trade
Commission.
ACTION: Notice.
SUMMARY: Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review an initial determination (‘‘ID’’)
(Order No. 3) issued by the presiding
administrative law judge (‘‘ALJ’’)
granting complainants’ motion to amend
the complaint and notice of
investigation.
FOR FURTHER INFORMATION CONTACT:
Michelle Walters, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street, SW.,
Washington, DC 20436, telephone (202)
708–5468. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
E:\FR\FM\07NON1.SGM 07NON1